-+ 0.00%
-+ 0.00%
-+ 0.00%
Anixa Biosciences Secures Canadian Patent for Ovarian Cancer Vaccine
Share
Listen to the news
Anixa Biosciences Secures Canadian Patent for Ovarian Cancer Vaccine
  • Anixa Biosciences secured a Canadian patent covering its ovarian cancer vaccine technology, expanding protection beyond the United States.
  • Exclusively licensed from Cleveland Clinic, the patent covers methods of immunizing against AMHR2-ED, a protein domain expressed in certain ovarian cancers.
  • The Canadian patent complements U.S. patent protection announced in July 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611190845PR_NEWS_USPR_____LA02109) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending